Abstract

The researchers at Duke University will collaborate in the planning and development of a Prostate Cancer Program at Duke University. Components for planning and development, the recruitment of new Investigators and funding to develop a Pilot Program will be established. Pilot projects will be particularly focused to address the issues of occupational exposure, diet, familial association and race as well as innovative concepts in therapy and cellular regulation. A specific orientation will be the ascertainment of African-American males to explain their apparently higher risk of onset of prostate carcinoma in that population. A wide research base in cancer will be the basis upon which to build hypothesis directed research pilot programs to gain sufficient information to justify application for formal R01 support for such prostate cancer directed research activities. An Internal Advisory Board has been established which will direct the planning and development of such activities.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA069773-01
Application #
2113785
Study Section
Special Emphasis Panel (SRC (06))
Project Start
1995-09-30
Project End
1999-08-31
Budget Start
1995-09-30
Budget End
1996-08-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Gilbert, Jill; Rudek, Michelle A; Higgins, Michaela J et al. (2012) A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1735-42
Fracasso, Paula M; Williams, Kerry J; Chen, Ronald C et al. (2011) A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 67:1225-37
Karp, Judith E; Smith, B Douglas; Resar, Linda S et al. (2011) Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117:3302-10
Smith, B Douglas; Jones, Richard J; Cho, Eunpi et al. (2011) Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res 35:87-94
Stearns, Vered; Mori, Tsuyoshi; Jacobs, Lisa K et al. (2011) Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med 3:106ra108
Bisht, Savita; Khan, Mehtab A; Bekhit, Mena et al. (2011) A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab Invest 91:1383-95
Connolly, Roisin M; Rudek, Michelle A; Garrett-Mayer, Elizabeth et al. (2011) Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 127:153-62
Ray, Balmiki; Bisht, Savita; Maitra, Amarnath et al. (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J Alzheimers Dis 23:61-77
Weekes, Colin D; Nallapareddy, Sujatha; Rudek, Michelle A et al. (2011) Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 29:1057-65
Armstrong, Andrew J; Netto, George J; Rudek, Michelle A et al. (2010) A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 16:3057-66

Showing the most recent 10 out of 29 publications